| Name | Alfuzosin |
| Description | Alfuzosin (SL 77499) is an orally available, competitive α1-adrenoceptor antagonist.Alfuzosin induces smooth muscle relaxation in the bladder neck and prostate.Alfuzosin has been used to study benign prostatic hypertrophy, lower urinary tract symptoms (LUTS), and ejaculatory dysfunction (EjD). |
| In vitro | In male Wistar rats weighing 250-450 g, Alfuzosin (10 mg/kg; oral administration; single dose) increased prostatic concentrations to 4.1-8.6 times higher than plasma concentration[1]. |
| In vivo | In male Wistar rats weighing 250-450 g, Alfuzosin (10 mg/kg; oral administration; single dose) increases prostatic concentrations to 4.1-8.6 times higher than plasma concentration[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 40 mg/mL (102.71 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2.5 mg/mL (6.42 mM), Sonication is recommended.
|
| Keywords | α1A-adrenergic receptor | AdrenergicReceptor | Adrenergic Receptor |
| Inhibitors Related | Trifluoperazine dihydrochloride | Mirtazapine | Octopamine hydrochloride | Gemfibrozil | Buflomedil hydrochloride | Dexmedetomidine hydrochloride | Isoprenaline hydrochloride | D-Mannitol | Mianserin hydrochloride | Trazodone hydrochloride | Atenolol | Doxepin hydrochloride |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Failed Clinical Trials Compound Library | Bioactive Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cardiovascular Disease Compound Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | GPCR Compound Library |